Hims & Hers Health Stock Slides 15%+ Intraday on Short Report from Hunterbrook
Hims & Hers Health Stock Slides 15%+ Intraday on Short Report from Hunterbrook
$Hims & Hers Health (HIMS.US)$ sank more than 15% intraday Thursday after Hunterbrook issued a so-called "short report" on the mail-order-drug retailer.
$Hims & Hers Health (HIMS.US)$郵購藥品零售商受到 Hunterbrook 的所謂"空頭報告"的影響，在週四盤中下跌超過15%。
HIMS fell as much as 16.5% to an $18.80 intraday low after Hunterbrook released a bearish report on Thursday, alleging problems with Hims & Hers' recent moves to sell hot GLP-1 weight loss drugs.
Hunterbrook在週四發佈了看淡報告，指稱 HIMS 最近銷售熱門 GLP-1 減肥藥存在問題，導致其股價下跌了高達 16.5%，至18.8美元的盤中低點。
Benzinga reached out to Hims & Hers Health for comment and received a response from a spokesperson highlighting a post on the company's commitment to customer safety and another post on how the company is delivering safe access to GLP-1 injections.
本文已聯繫 Hims & Hers Health 進行評論，並從一位發言人處收到回覆，強調了公司對客戶安全的承諾，以及公司如何提供安全使用 GLP-1 注射劑的功能。
Hunterbrook operates under two different arms: Hunterbrook Media and Hunterbrook Capital.
Hunterbrook 有兩個不同的部門：Hunterbrook Media 和 Hunterbrook Capital。前者作爲一個媒體機構，發佈全球新聞報道。後者作爲一個投資基金，通過賭博一些研究報告中的股票方向進行盈利。
The former operates as a media outlet publishing investigative and global reporting. The latter arm is a hedge fund that bets for or against some of the stocks on which it reports. Hunterbrook has announced that it has a short position in Hims & Hers Health stock.
Hunterbrook 宣佈在 Hims & Hers Health 的股票中有空頭頭寸。